Sumitomo Pharma America, Inc.
PharmaJersey City, New Jersey, United States · Est. 2007
Sumitomo Pharma America is the US subsidiary of Japanese pharmaceutical company Sumitomo Pharma focused on developing and commercializing innovative pharmaceutical treatments in psychiatry, neurology, and oncology.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
176
Clinical Trials↗
All sponsored trials (all statuses)
22
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
No phase data available.
By Therapeutic Area
top 3
Oncology
250%
Ophthalmology
125%
Hematology
125%
R&D Momentum
38/100
Pipeline Velocity
11/100
Trial Completion Rate
89/100
Pipeline Concentration
38/100
Pipeline Freshness
69/100
Strategic Signals
- ↗Active in Ophthalmology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Completed
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Earlier
Mar 2, 2026TrialHow [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
Oct 23, 2025TrialA Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Aug 14, 2024TrialSMP-3124LP in Adults With Advanced Solid Tumors
Mar 4, 2024TrialTP-3654 Food Effect Study
May 22, 2023TrialAssessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
Jan 25, 2023TrialRandomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Mar 17, 2022TrialA Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
4 more events
Feb 28, 2022TrialA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Dec 21, 2021TrialA Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
Sep 8, 2021TrialStudy of DSP-0390 in Patients With Recurrent High-Grade Glioma
Feb 18, 2021TrialStudy of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
CEOTaro Yamada
Founded2007
HQJersey City, New Jersey, United States
Websitesumitomoharma.com
LinkedInCompany Page
Therapeutic Focus
PsychiatryNeurologyOncology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Oncology
Ophthalmology
Regulatory
Regulatory Timeline
20131 event
FDANov 8
Aptiom — APTIOM
Application NDA022416 (NDA)
20202 events
FDADec 23
Gemtesa — GEMTESA
Application NDA213006 (NDA)
FDADec 18
Orgovyx — ORGOVYX
Application NDA214621 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)